Sun Pharma revises offer to buy outstanding shares of Taro Pharma; stock falls
Sun proposes to acquire outstanding shares of Taro’s at $43 apiece, up from $38 per share earlier
sun pharma q2 profit
December 2023
November 2022
Sun Pharma Q2 profit rises 10.5% to ₹2,262 cr; revenue up 13%
Sun Pharma MD Dilip Shanghvi says in Q2, Sun Pharma recorded double-digit topline growth and strong margins, driven by market share gain in India, and sustained ramp-up of global specialty biz.
